Tianqing Q. Chu

No. 241 Huaihai West Road
Xuhui, 200030, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 119 publications

PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.

PD-L1 expression is associated with inferior outcomes independent of EGFR subtype in advanced non-small cell lung cancer with uncommon EGFR mutations treated with first-line second-generation EGFR-tyrosine kinase inhibitors.

Journal: Cancer

Published: February 10, 2026

TRMT1-mediated tRNA m22G modification drives Osimertinib resistance via the ATXN3/USP25 axis in lung adenocarcinoma.

TRMT1-mediated tRNA m22G modification drives Osimertinib resistance via the ATXN3/USP25 axis in lung adenocarcinoma.

Journal: Cell death & disease

Published: January 15, 2026

The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes.

The impact of SGLT2i on the outcome of advanced lung cancer in patients with diabetes.

Journal: Frontiers in oncology

Published: December 03, 2025

Genomic profiles of primary and acquired MET mutations in NSCLC and the impact of co-mutations on treatment outcomes

Genomic profiles of primary and acquired MET mutations in NSCLC and the impact of co-mutations on treatment outcomes

Journal: Zhonghua yi xue za zhi

Published: November 30, 2025

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis.

Journal: Nature communications

Published: November 28, 2025

Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogramming.

Regulation of neuronal invasion of small cell lung cancer by STMN2/β-alanine-controlled metabolic reprogramming.

Journal: Cell reports

Published: November 10, 2025

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.

Benmelstobart plus anlotinib versus pembrolizumab as first-line treatment for PD-L1-positive, advanced non-small-cell lung cancer (CAMPASS): a blinded, randomised, controlled, phase 3 trial.

Journal: The Lancet. Oncology

Published: November 05, 2025

Multi-omics dynamic profiling reveals predictive biomarkers for first-line immunochemotherapy in extensive-stage small-cell lung cancer.

Multi-omics dynamic profiling reveals predictive biomarkers for first-line immunochemotherapy in extensive-stage small-cell lung cancer.

Journal: Journal of translational medicine

Published: October 12, 2025

Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment.

Angiotensin receptor-neprilysin inhibitors improve the outcome of lung cancer patients with hypertension undergoing immune checkpoint inhibitors treatment.

Journal: BMC cardiovascular disorders

Published: October 08, 2025

Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study.

Real-world outcomes of trastuzumab deruxtecan as second- or further-line treatment in patients with HER2-mutant metastatic non-small cell lung cancer: a retrospective study.

Journal: Translational lung cancer research

Published: August 06, 2025

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Journal: Cancer discovery

Published: August 02, 2025

New-Onset Arrhythmias in Advanced Lung Cancer Patients Undergoing Anlotinib Treatment.

New-Onset Arrhythmias in Advanced Lung Cancer Patients Undergoing Anlotinib Treatment.

Journal: Cardiovascular toxicology

Published: July 06, 2025

Showing 1-12 of 119

Last Updated: 09/26/2026